PMID- 32414649
OWN - NLM
STAT- MEDLINE
DCOM- 20211008
LR  - 20211008
IS  - 1938-0666 (Electronic)
IS  - 1526-8209 (Linking)
VI  - 20
IP  - 4
DP  - 2020 Aug
TI  - Research Progress on Long Non-coding RNAs and Drug Resistance of Breast Cancer.
PG  - 275-282
LID - S1526-8209(19)30732-3 [pii]
LID - 10.1016/j.clbc.2019.11.001 [doi]
AB  - Breast cancer, as the foremost cause of women's death in the world, is highly 
      metastatic and mutable. Resistance to drugs for chemotherapies, endocrine 
      therapies, and targeted therapies is an important factor that impacts the 
      prognosis of breast cancer. Long non-coding ribonucleic acids (LncRNAs) are 
      crucial regulators of intracellular gene expressions. Some researchers have 
      suggested that expression level of several types of LncRNAs were closely related 
      to the prognosis of patients with breast cancer. LncRNAs significantly impact 
      biological processes such as drug transport, detoxication, apoptosis, epithelial 
      to mesenchymal transition (EMT), and autophagy by regulating intracellular 
      signaling pathways such as multi-drug resistance gene 1 (MDR1), nuclear factor 
      erythroid 2-related factor 2 (NRF2), phosphoinositide 3-kinase 
      (PI3K)/Akt/mammalian target of rapamycin (mTOR), transforming growth factor-beta 
      (TGF-beta), BRCA1/2, and nuclear factor kappa-light-chain-enhancer of activated B 
      cells (NF-kappaB). This paper will summarize research progress on correlations 
      between LncRNA and drug resistance of breast cancer. It will particularly expound 
      molecular mechanisms through which LncRNAs regulate drug resistance of breast 
      cancer. It will further discuss the feasibility as molecular markers for 
      forecasting drug resistance of breast cancer and may be becoming new targets for 
      treating breast cancer in the future.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Zhang, Xiping
AU  - Zhang X
AD  - Department of Breast Surgery, Cancer Hospital of University of Chinese Academy of 
      Sciences, Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, China.
FAU - Yang, Hongjian
AU  - Yang H
AD  - Department of Breast Surgery, Cancer Hospital of University of Chinese Academy of 
      Sciences, Zhejiang Cancer Hospital, Hangzhou, Zhejiang Province, China. 
      Electronic address: yhjzlyy@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200430
PL  - United States
TA  - Clin Breast Cancer
JT  - Clinical breast cancer
JID - 100898731
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (RNA, Long Noncoding)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*pharmacology/therapeutic use
MH  - Apoptosis/drug effects/genetics
MH  - Autophagy/drug effects/genetics
MH  - Biomarkers, Tumor/analysis/antagonists & inhibitors/*metabolism
MH  - Breast Neoplasms/diagnosis/*drug therapy/genetics/pathology
MH  - Cell Proliferation/drug effects/genetics
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Epithelial-Mesenchymal Transition/drug effects/genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Prognosis
MH  - RNA, Long Noncoding/analysis/antagonists & inhibitors/*metabolism
MH  - Signal Transduction/genetics
OTO - NOTNLM
OT  - Breast cancer
OT  - Drug resistance
OT  - Epithelial to mesenchymal transitions (EMT)
OT  - Long non-coding ribonucleic acids (LncRNAs)
OT  - Molecular mechanisms
EDAT- 2020/05/18 06:00
MHDA- 2021/10/09 06:00
CRDT- 2020/05/17 06:00
PHST- 2019/08/31 00:00 [received]
PHST- 2019/10/23 00:00 [revised]
PHST- 2019/11/06 00:00 [accepted]
PHST- 2020/05/18 06:00 [pubmed]
PHST- 2021/10/09 06:00 [medline]
PHST- 2020/05/17 06:00 [entrez]
AID - S1526-8209(19)30732-3 [pii]
AID - 10.1016/j.clbc.2019.11.001 [doi]
PST - ppublish
SO  - Clin Breast Cancer. 2020 Aug;20(4):275-282. doi: 10.1016/j.clbc.2019.11.001. Epub 
      2020 Apr 30.